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Abstract
Background: Amoebic liver abscess (ALA) is the most frequent clinical presentation of extra-intestinal amoebiasis.
The diagnosis of ALA is typically based on the developing clinical symptoms, characteristic changes on radiological
imaging and serology. Numerous serological tests have been introduced for the diagnosis of ALA, either detecting
circulating amoebic antigens or antibodies. However those tests show some pitfalls in their efficacy and/or the
preparation of the tests are costly and tedious. The commercial IHA kit that used crude antigen was reported to be
useful in diagnosis of ALA, however high antibody background in endemic areas may cause problems in its
interpretation. Thus, discovery of well-defined antigen(s) is urgently needed to improve the weaknesses of current
serodiagnostic tests.
Methods: Crude antigen of E. histolytica was analysed by 2-DE and Western blot to identify a protein of diagnostic
potential for ALA. The corresponding gene of the antigenic protein was then cloned, expressed and the purified
recombinant protein was subsequently evaluated for serodiagnosis of ALA in an indirect ELISA format.
Results: Analysis of crude antigen showed that phosphoglucomutase (PGM) has the diagnostic potential.
Recombinant PGM (rPGM) showed 79.17% (19/24) sensitivity and 86.67% (195/225) specificity in diagnosis of ALA
based on the COV of mean +1SD. There was no significant difference between rPGM-ELISA and IHA diagnostic kit
in the diagnosis of ALA in terms of sensitivity and specificity at p-value < 0.05.
Conclusion: In conclusion, rPGM-ELISA is found to be useful for serodiagnosis of ALA. Future studies will determine
whether rPGM-ELISA also detects antibodies produced in amoebic dysentery and asymptomatic cases.
Keywords: Entamoeba histolytica, Amoebic liver abscess, 2-DE, Western blot, Phosphoglucomutase, Diagnosis,
rPGM-ELISA
Background
Liver abscess is commonly detected by radiological
imaging technique, but it cannot differentiate between
amoebic and pyogenic liver abscesses. Differential diagno-
sis depends on clinical grounds and amoebic serology [1].
The serological tests revealed varied sensitivity levels, de-
pending on the presence or absence of invasive disease
and the types of invasive disease. Interestingly, more than
90% of patients with amoebic liver abscess (ALA) devel-
oped detectable anti-amoebic antibodies at 7 – 10 days
after onset of symptoms. This augurs well for the develop-
ment of serodiagnosis against the infection [2-4].
Numerous studies indicated high sensitivity and specifi-
city of crude amoebic antigen e.g. crude soluble antigen
and excretory-secretory antigens in capturing amoebic
antibodies for diagnosis of ALA [5-8]. However, the
pitfalls of crude antigen are the need to maintain E.
histolytica cultures and the mass production of the anti-
gen, which are costly and tedious. Occasionally, this cock-
tail antigen preparation reveals false positivity [9]. IHA
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GmbH, Germany) that uses crude antigen was reported to
be useful in diagnosis of ALA, yet due to the high back-
ground in endemic areas, the diagnostic validity varied
between 70% and 90% among different geographical loca-
tions [10-12]. Hence, a standardised serological test based
on well-defined antigen(s) is needed to overcome the
weaknesses.
Recombinant DNA technology offers large-scale pro-
duction of defined antigens through prokaryotic expres-
sion system. Serodiagnosis of invasive amoebiasis using
defined recombinant E. histolytica antigens of serine-rich
protein (SREHP), Gal/GalNAc-specific lectin and 29 kDa
cysteine-rich surface protein has been reported since
1990s [13]. The recombinant protein of SREHP showed
sensitivity of 79% and specificity of 87% in diagnosis of
ALA, yet its overall diagnostic validity was lower than the
conventional tests that utilized crude antigen [14]. Even
though both recombinant Gal/GalNAc-specific lectin and
29 kDa cysteine-rich surface proteins showed high validity
of ≥ 90% sensitivity and specificity in serodiagnosis of
amoebic dysentery and asymptomatic amoebiasis, they
were not specific in the diagnosis of ALA [15,16].
Therefore, this study attempted to identify and analyse
potential new antigenic protein(s) from crude antigen of
E. histolytica using human ALA serum samples. The
corresponding gene of the antigenic protein(s) was then
cloned and expressed, followed by the diagnostic poten-




Positive serum samples were obtained from 24 patients
warded in Hospital Universiti Sains Malaysia (HUSM)
who were diagnosed with ALA based on clinical symp-
toms; detectable abscess by ultrasound imaging; and
positive serology with a commercial indirect haemagglu-
tination kit, IHA (CellognostW Amoebiasis Kit, Dade
Behring Marburg GmbH, Germany). On the other hand,
non-ALA serum samples with IHA seronegative were
obtained from 33 patients, in which four serum samples
were obtained from patients with pyogenic liver abscess
(n = 4) whereas the others were obtained from patients
infected with pathogens other than E. histolytica, which
include enteropathogenic Escherichia coli (n = 1), Shigella
sonnei Group D (n = 1), Salmonella spp. (n = 5), Klebsiella
pneumoniae (n = 1), Staphylococcus aureus (n = 1), Ascaris
lumbricoides (n = 1), Escherichia coli (n = 2), Coagulase-
negative Staphylococcus (n = 1), Stenotrophomonas
maltophilia (n = 1), Toxoplasma gondii (n = 9) and
Helicobacter pylori (n = 6). In this study, all the six H.
pylori sera were pooled into a single tube because the
individual volumes were too little. In addition, a to-
tal of 197 blood donor serum samples were obtained
from Department of Haematology & Blood Transfu-
sion Unit at HUSM. All the human serum samples
were collected and checked with IHA from the year
2008 onwards and kept at −20°C until used. This
study was conducted in accordance with the require-
ment of Universiti Sains Malaysia Human Research
Ethics Committee, USMKK/PPP/JEPeM (213.3. [10]).
Maintenance of E. histolytica and preparation of crude
soluble antigen (CSA)
E. histolytica HM-1:IMSS was axenically cultured and
maintained in Diamond’s TYI-S-33 medium [17]. For CSA
preparation, 10 × 106 of E. histolytica trophozoites were
mixed with 500 μL complete Lysis-M buffer supplemented
with protease inhibitor cocktail (Roche, Germany) and 20
μL of 0.5 M iodoacetamide (Sigma, USA). The mixture was
then sonicated (Branson, Mexico) at 10% amplitude for
three cycles of 1 min sonication with 0.5 sec pulse-on and
0.5 sec pulse-off. The lysate was centrifuged at 10 000 × g
for 10 min at 4°C to collect the CSA in the supernatant.
Subsequently, the protein concentration was estimated
using Bradford protein assay [18].
Analysis of CSA antigenic protein profile via SDS-PAGE
and Western blotting
Twenty micrograms of CSA per well was separated by
9% sodium dodecyl sulfate polyacrylamide gel electro-
phoresis (SDS-PAGE) using Bio-Rad Mini-Protean III
Electrophoresis Cell (Bio-Rad, USA) at a constant
current of 25 mA per gel for about 1 h and the sepa-
rated proteins were electroblotted onto a 0.45 μm-
pore-size nitrocellulose (NC) membrane via a semidry
transblot apparatus (Bio-Rad, USA) at constant voltage
of 15 V for 45 min. The NC membrane was blocked for
1 h at RT with 5% skim milk with 10 mM Tris-buffered
saline (TBS), pH 7.2 as the diluent. Subsequently, the
NC membrane was cut into multiple strips and incu-
bated with human sera at a dilution of 1:200 in TBS
containing 0.1% Tween 20 (TBST) for 2 h at RT. The
excess serum was removed by washing (3 × 5 min) the
strips with TBST. Next, the strips were incubated with a
monoclonal mouse anti-human IgG conjugated with
horseradish peroxidase (HRP) (Invitrogen, USA) at a
dilution of 1:6000 for 1 h at RT. The unbound second-
ary antibodies were removed by washing (3 × 5 min)
with 0.1% TBST. The Western blot signal was detected
by enhanced chemiluminescence (ECL) reagent (Roche
Diagnostics, Germany), captured using X-ray film
(Kodak, USA). The sensitivity and specificity of the anti-
genic protein was then evaluated based on serum sam-
ples collected from ALA cases (n = 24), patients with
infections other than amoebiasis (n = 33) and blood
donors (n = 30).
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Identification of the antigenic protein via 2-DE and
Western blotting
A 2-DE gel electrophoresis was performed to further
separate the antigenic protein band. Proteins of CSA were
first fractionated based on their isoelectric point (pI)
using 3100 OFFGEL Fractionator (Agilent Technologies,
Germany). The ImmobilineTM Dry Strip (GE Healthcare,
UK) with linear pH range 3–10 with a 12-well setup was
used. The fractionation of CSA was performed according
to the manual provided by the manufacturer. In brief, the
protein sample was prepared by gently mixing 1600 μL of
OFFGEL stock solution (1.25X) with 400 μL of the CSA
sample with total protein mass of 2 mg. A volume of 150
μL of OFFGEL sample was loaded into each well of IPG
strip after gel rehydration with 40 μL of IPG strip rehydra-
tion buffer. Mineral oil used as cover fluid was pipetted
onto the gel strip ends. The sample was focused with a
maximum power of 200 mW, maximum current of 50 μA
and typical voltages ranging from 500 to 4500 V until 50
kVh was reached in ~24 h. The typical starting voltages
used were from 200 to 1500 V. A volume of 20 μL of the
fractionated protein sample was mixed with 5 μL of 5X
SDS sample buffer without boiling, and subsequently sep-
arated by SDS-PAGE. The separated proteins were then
transferred onto NC membrane followed by Western blot
analysis using pooled and individual ALA or IHA sero-
negative serum samples at 1:200 dilution.
Mass spectrometry analysis and protein identification
The antigenic protein band was excised from the 2-D SDS-
PAGE gel and sent to Australian Proteomic Service for
peptide sequencing by mass-spectrometry. At the prote-
omic facility, protein sample was digested with trypsin and
the peptides were extracted and analysed by electrospray
ionisation mass spectrometry (ESI-TRAP) using the Ulti-
mate 3000 nano HPLC system (Dionex) coupled to a 4000
Q TRAP mass spectrometer (Applied Biosystems). The
mass-spectrometry analysis was performed with two differ-
ent gel slice samples to ensure reproducibility.
Cloning of selected gene
Based on the amino acid sequence of the ~70 kDa anti-
genic protein, the encoding gene was identified. PCR
primers were then designed based on the protein coding
sequence retrieved from the GenBank (accession num-
ber XM_643579) to amplify the gene of interest from E.
histolytica genomic DNA isolated from 3 × 106 of E.
histolytica trophozoites using a QIAamp DNA mini kit
(QIAGEN GmbH, Germany). The optimum annealing
temperature was 52°C. For cloning into pET-14b vector,
XhoI (CTCGAG) and BamHI (GGATCC) recognition
sequences were added to the forward and reverse
primers, respectively. The primers sequences used to
generate a 1785 bp PCR product were 50- CCG CTC
GAG ATG GCA CTG AAT AAT TAT ATT AAG-30 for-
ward primer; and 50- CGC GGA TCC TTA CTC AGC
TTT TGG TGG-30 reverse primer. The amplified prod-
uct with the expected size was cut and extracted from
the 1% agarose gel using QIAGEN gel extraction kit
(QIAGEN GmbH, Germany). Before ligation, both the
PCR amplified product and pET-14b vector were
digested with XhoI and BamHI (Fermentas Life Sciences,
USA). The digested products were then purified by PCR
purification kit (QIAGEN GmbH, Germany).
Ligation was performed by mixing the digested plasmid
and PCR amplified product in the ratio of 1:3 in a final vol-
ume of 10 μL containing 1X T4 DNA Ligase buffer,
5 U of T4 DNA Ligase and dH2O. The ligation mixture
was incubated overnight at 4 °C. Next, E. coli XL 1-Blue
competent cells were transformed with the ligation mixture
by heat-shock method. Colony PCR using T7 promoter
primer (50-TAATACGACTCACTATAGG-30) and T7 ter-
minator primer (50-GCTAGTTATTGCTCAGCGG-3) was
performed to screen for positive transformants, and the
positive clones were confirmed by DNA sequencing.
Expression and purification of recombinant antigenic
protein
Recombinant plasmid carrying the open reading frame
for the antigenic protein was transformed into expres-
sion host (E. coli BL-21 AI strain). The bacteria was
grown at 37°C until OD600 nm reached 1.2 and protein
expression was induced with 0.2% (w/v) L-arabinose at
22°C for overnight. The recombinant protein was puri-
fied using nickel-nitrilotriacetic acid (Ni-NTA) affinity
purification method. In brief, 800 mL of culture were
harvested by centrifugation at 1800 × g, 20 min, at 4°C.
The supernatant was discarded and the cell pellet was
mixed and resuspended in 10 mL of lysis buffer [50 mM
Tris–HCl (pH 7.5), 300 mM NaCl, 10 mM Imidazole
and 1% Triton X-100] supplemented with 7.8 μL of β-
mercaptoethanol. The suspension was then sonicated
and centrifuged at 1800 × g, 30 min, at 4°C. The super-
natant was transferred into a clean 15 mL centrifuge
tube. A volume of 100 μL of Ni-NTA agarose (QIAGEN,
Germany) was mixed with the supernatant and the sus-
pension was then rotated at 4°C for 2 h. After that, the
suspension was centrifuged at 450 × g, 2 min, at 4°C.
The supernatant was discarded and the Ni-NTA agarose
was washed with 10 mL of ice-cooled His-Tag washing
buffer [50 mM Tris–HCl (pH 7.5), 300 mM NaCl and
20 mM Imidazole]. The suspension was rotated at 4°C
for 30 min. The supernatant was discarded and the
washing step on Ni-NTA agarose was repeated for an-
other 5 times. In the final washing step, the suspension
was centrifuged at 450 × g, 2 min, at 4°C and the super-
natant was discarded. The recombinant protein that
bound to the Ni-NTA agarose was eluted by 120 μL of
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ice-cooled His-Tag elution buffer [50 mM Tris–HCl
(pH 7.5), 300 mM NaCl and 200 mM Imidazole] and
rotated at 4°C for 3 h. The suspension was then
centrifuged at 450 × g, 5 min, at 4°C and the concentra-
tion of the supernatant (eluted protein) collected in a
clean 1.5 mL micro-centrifuge tube was determined by
Bradford protein assay.
Development and evaluation of indirect recombinant
antigen based ELISA
Indirect-ELISA was performed on the human serum sam-
ples using the purified recombinant protein based on modi-
fications of method described by Reen [19]. The coating
concentration of the antigen for each well of a microtiter
plate was 1 μg/mL; and the primary and secondary anti-
body dilutions were 1:50 and 1:250, respectively. In brief,
each well of a 96-well flat-bottom microtiter plate (NUNC,
Denmark) was coated with 100 μL of antigen diluted in
0.1 M bicarbonate buffer (pH 9.6). The plate was then
covered and incubated overnight in a humid box at 4°C.
Prior to the blocking step, coated plate was equilibrated for
1 h at room temperature and then each well was rinsed
(5 × 5 min) with 200 μL phosphate buffered saline added
with 0.05% Tween-20 (PBST). The plate was blotted against
a piece of paper towel after every round of rinsing. After
1 h in blocking reagent (Roche, Germany), each well was
washed with 0.05% PBST (5 × 5 min), followed by another
hour of incubation with 100 μL of diluted serum samples,
performed in duplicate. After another round of washing,
100 μL of PBS diluted HRP-conjugated mouse monoclonal
anti-human IgG (Invitrogen, USA) was added into the well
and incubated for 1 h. Following a final round of washing,
100 μL of TMB substrate was added and the plate was
incubated in the dark at room temperature for 15 min. The
optical densities (OD) were finally read at 450 nm
VersaMax™ Microplate Reader (Sunnyvale, USA). The and
specificity of the recombinant antigen in an indirect ELISA
format was then evaluated against the IHA kit using the
different categories of serum samples collected. The COV
for the indirect ELISA was set at either mean OD value
plus one or two standard deviations (SD) from the OD
values obtained from 113 IHA seronegative blood donor
serum samples.
Statistical analysis
Statistical analysis was performed with SPSS for Windows
version 18.0. The association between the indirect ELISA
and IHA in clinical diagnosis of ALAwas analysed using chi-
square test; if indicated Fisher’s exact test was used instead.
Results
IgG blots of CSA
Immunoblotting results showed that there were three
antigenic proteins i.e. ~170 kDa, ~100 kDa and ~70 kDa,
recognized by individual human ALA serum samples
(Figure 1). Based on the 24 human ALA serum samples,
the sensitivities of these three antigenic proteins were
70.83%, 62.5% and 70.83%, respectively; while their spe-
cificities were 100%, 100% and 96.83%, respectively, when
tested against a total of 63 negative control serum
samples. The results on the sensitivity and specificity are
summarised in Table 1.
2-DE Western blot analysis and protein identification
Both the ~170 kDa and ~70 kDa proteins revealed almost
similar sensitivity and specificity. Since the ~170 kDa was
most probably the previously studied lectin antigen [16]
and ~100 kDa showed lower sensitivity, hence here, only
the ~70 kDa protein was further studied. In 2D-Western
blotting analysis, the 70 kDa protein was presented in
fraction 7 with pH between 6.5 and 7.08. Western blot in
fraction 7 using two individual human ALA serum sam-
ples revealed positive reactivity against the targeted anti-
genic protein (Figure 2). Mass-spectrometry analysis
identified the ~70 kDa antigenic protein as phosphogluco-
mutase (PGM) of E. histolytica (accession number
C4M3Z6) with the protein score of 793 and 19 peptide se-
quences matched to the amino acid sequence. The score
> 55 indicates identity or extensive homology at a signifi-
cant level of p < 0.05. The total sequence coverage of the
protein was reported as 25%.
Expression and purification of the recombinant PGM
(rPGM) protein
The rPGM protein tagged with six consecutive histidine
residues was purified using Ni-NTA affinity purification
and was evaluated by 9% SDS-PAGE (Figure 3). The re-
sult showed that about 50% of the expressed PGM was
present in the soluble fraction (lane 3). In lane 4, it re-
vealed the soluble recombinant protein was successfully
purified to apparent homogeneity.
Efficacy of rPGM-ELISA
The COVs of rPGM-ELISA at mean OD value + 1SD
and mean OD value + 2D were determined to be 0.25
and 0.32, respectively. The sensitivity was calculated
based on results of 24 human ALA serum samples; while
a total of 225 human sera from other infections and
blood donors were used for specificity test. Based on the
COV of mean + 1SD and mean + 2SD, the sensitivities of
rPGM-ELISA were 79.17% (19/24) and 45.83% (11/24),
respectively; while the specificities of the tests were
86.67% (195/225) and 93.78% (211/225), respectively
(Table 2). Thus the COV based on mean + 1SD was se-
lected over the COV of mean + 2SD as it showed better
sensitivity and specificity in diagnosis of ALA. In com-
parison with IHA kit, statistical analysis showed that
there was no significant difference between rPGM-
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ELISA and IHA in terms of sensitivity and specificity at
p-value < 0.05 (Table 3).
Discussion
Conventionally, diagnosis of ALA is confirmed by finding
the E. histolytica trophozoites in liver pus aspirate
obtained via ultrasound guided percutaneous aspiration
biopsy, but the parasites are often absent as most of them
are located at the margin on the peripheral of the abscess
[20,21]. Therefore, serodiagnosis is widely adopted for
diagnosis of ALA, detecting either amoebic antigens or
antibodies from serum samples. Although numerous
commercial antigen detection kits have been developed
i.e. TechLab E. histolytica II ELISA (TechLab, Blacksburg,
VA), Entamoeba CELISA-PATH (Cellabs Pty Ltd.,
Brookvale, Australia), Optimum S Entamoeba histolytica
antigen ELISA (Merlin Diagnostika, Berheim-Hersel,
Germany), Triage parasite panel BIOSATE (diagnostic,
San Diego, CA), and ProSpecT Entamoeba histolytica
microplate assay (REMEL Inc., Lenexa, KS), only TechLab
E. histolytica II ELISA was evaluated for the detection of
circulating antigen in ALA patient serum samples [22].
Haque et al. [23] reported that the kit detected Gal/
GalNAc lectin in the ALA patient serum samples with a
sensitivity of 96%. However, reports by Parija and Khairnar
[24] and Zeehaida et al. [25] revealed lower sensitivities at
50% and 8.6%, respectively.
Instead of antigen detection, diagnosis of ALA can be
performed by detecting circulating antibodies because
hepatic amoebiasis raises a strong humoral response, es-
pecially immunoglobulin G [26]. Although a variety of
serological assays was reported in diagnosis of ALA
based on detecting circulating antibodies i.e. IHA, latex
agglutination, indirect immunofluorescence, counter-
immunoelectrophoresis, gel diffusion, complement fix-
ation and ELISA; IHA and ELISA are still the preferred
choices [22]. ELISA is commonly used as the routine
diagnostic assay in diagnosis of ALA because it can be
developed for in-house use based on different amoebic
antigen preparations such as CSA, excretory-secretory
antigens, plasma membrane antigens, purified antigenic
proteins or recombinant proteins.
The CSA-based ELISA technique has either been used
in routine diagnosis of ALA or field screening of
amoebiasis [8,10,27,28]. In the diagnosis of ALA, CSA-
based ELISA was reported to be 100% sensitive and >
90% specific [8,29]. Excretory-secretory antigens have
been reported to be useful in diagnosis of ALA, which
Figure 1 Western blot profile of CSA probed with representative individual human serum. Lane MW: Molecular weight standard
(PageRulerTM Prestained Protein Ladder); Lane 1: Pooled human ALA serum; Lane 2: Pooled human IHA seronegative serum; Lanes 3 to 9:
Individual human ALA serum; Lanes 10–12: Individual human IHA seronegative serum; Lane 13: TBS control. (*) indicates the estimated molecular
weight of proteins (~170 kDa, ~100 kDa and ~70 kDa).










Sensitivity (%) Specificity (%)
170 17 0 70.83 100
100 15 0 62.5 100
70 17 2 70.83 96.83
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showed sensitivity of ~80% in Western blot analysis
[7,30]. Another ELISA using amoebic plasma membrane
antigen for diagnosis of ALA was reported to be 95%
sensitive and 91% specific against anti-amoebic IgG;
while detection of anti-amoebic IgM was 91% sensitive
and 95% specific [31].
Nonetheless, crude preparations of amoebic antigens
produced variable diagnostic efficacies, which may lead
to false positive in the diagnosis of ALA. These antigen
preparations require maintenance of E. histolytica cul-
tures, which is costly and tedious. Moreover, the pro-
teins are not well-defined; hence the interpretation of
results may vary from batch to batch. In this study, ana-
lysis of the CSA protein profile showed that most of the
antigenic proteins recognized by the human ALA serum
antibodies ranged from 25 kDa to 170 kDa. Lower per-
centage (9%) polyacrylamide gel revealed that the
~170 kDa, ~100 kDa and ~70 kDa protein bands were
well recognized by human ALA serum samples. Here,
the ~70 kDa protein with 70.83% sensitivity and 96.83%
specificity was selected for cloning and production of
recombinant protein. The ~170 kDa protein also re-
vealed almost similar sensitivity and specificity, but
was not selected because it was most probably similar to
the previously described lectin surface antigen of E.
histolytica [16].
Prior to elucidating the identity of the ~70 kDa protein,
it was further separated using 2-DE electrophoresis, a
widely used technique in biomarker discoveries [32]. Pro-
teins of CSA were fractionated via OFFGEL approach
based on pI separation. This approach is advantageous
when serum sample is limited. Multiple individual serum
samples can be applied on the selected pI protein fraction
containing the protein of interest in NC strip blot format,
instead of using the whole gel NC membrane format in
the conventional 2D-Western blot.
The ~70 kDa protein in this study was identified as E.
histolytica PGM by mass-spectrometry analysis. This pro-
tein is reported to be involved in the glycolytic pathway of
E. histolytica, which catalyses the inter-conversion of glu-
cose 6-phosphate and glucose 1-phosphate. Previously,
PGM was used as the gold standard for differentiation be-
tween E. histolytica and E. dispar via isoenzyme electro-
phoresis together with hexokinase [33]. Interestingly,
there is no report on the value of this protein in diagnosis
of invasive amoebiasis.
Well-defined antigens such as purified antigenic pro-
teins and recombinant proteins of E. histolytica can
overcome some of the setbacks posed by utilization of
crude soluble preparations. For instance, purified lectin
antigen and purified 29 kDa cysteine-rich surface protein
in an ELISA format were reported to be useful for diag-
nosis of ALA [34,35]. According to Flores et al. (1993),
the purified native 29 kDa cysteine-rich surface protein
showed 79% sensitivity and 98% specificity in the diag-
nosis of ALA [34]. Several recombinant proteins have
been produced such as SREHP, Gal/GalNAc-specific lec-
tin, 29 kDa cysteine-rich surface protein and 40 kDa
NADP+-dependent alcohol dehydrogenase (EhADH1)
[13,36]. Recombinant proteins of SREHP, Gal/GalNAc-
specific lectin and 29 kDa cysteine-rich surface protein
have been evaluated for diagnosis of ALA. SREHP/MBP
fusion protein, which was among the first recombinant
proteins used in serodiagnosis of ALA was reported to
have a sensitivity and specificity of 74% and 55%, re-
spectively. Interestingly, its diagnostic validity increased
to 79% and 87%, respectively, after the removal of its
MBP component [14]. The validity is almost similar with
rPGM protein in the current study, which is 79.17% sen-
sitive and 86.67% specific. Recombinant full-length
170 kDa Gal/GalNAc-specific lectin protein has been
produced and its validity in diagnosis of ALA was about
91% sensitivity [16]. Besides, several recombinant frag-
ments of the Gal/GalNAc-specific lectin protein have
also been investigated for the diagnosis of ALA. For
Figure 2 Antigenic protein profile of fractionated CSA probed
with human ALA serum. Lane M: Molecular weight standard
(PageRulerTM Prestained Protein Ladder); Lane 1: Pooled human
ALA serum; Lanes 2–3: Individual human ALA serum; (*) indicates
the targeted protein (~70 kDa).
Ning et al. BMC Infectious Diseases 2013, 13:144 Page 6 of 9
http://www.biomedcentral.com/1471-2334/13/144
example, recombinant protein of a truncated immuno-
dominant domain of the Gal/GalNAc-specific lectin pro-
tein with 1.85 kbp cDNA insert showed more than 90%
for both sensitivity and specificity [28]. Another study
using recombinant Gal/GalNAc-specific lectin-derived
protein (LC3) showed 100% sensitivity in diagnosis of
ALA [37]. A study carried out by Tachibana et al. [29]
reported that the 150 kDa recombinant intermediate
subunit (IgI) of the Gal/GalNAc-specific lectin protein
used in diagnosis of ALA was only 8.6% sensitive. A re-
combinant 29 kDa cysteine-rich surface protein was also
developed and evaluated as its purified form showed mod-
erate validity in diagnosis of ALA. The evaluation of this
recombinant protein in the diagnosis of ALA showed in-
crement of sensitivity (90%) compared to its purified na-
tive form protein (79%) [34].
Although several recombinant proteins have been
evaluated, they were not specific for diagnosis of ALA
because several studies have reported that those recom-
binant proteins were immunoreactive with serum sam-
ples for amoebic dysentery and asymptomatic cases
[15,16,29,38,39]. In the current study, the novel rPGM
protein showed diagnostic validity of ~80% sensitivity
and ~90% specificity in diagnosis of ALA. The efficacy
Figure 3 Purified recombinant PGM protein. Lane MW: PageRulerTM Prestained Protein Ladder; Lane 1: Non-induced cell pellet; Lane 2:
Induced cell pellet; Lane 3: Induced cell supernatant; Lane 4: Purified protein; Arrow indicates the recombinant PGM protein (~70 kD).
Table 2 Number of serum sample at different COV
settings from different serum test groups using
rPGM-ELISA
rPGM-ELISA (COV =mean + 1SD) Number of
Serum samples
Total
< 0.25 ≥ 0.25
Human ALA serum 5 19 24
Other infections human serum 21 7 28
Blood donors’ serum 174 23 197
Total 200 49 249
rPGM-ELISA (COV = mean + 2SD) < 0.32 ≥ 0.32
Human ALA serum 13 11 24
Other infections human serum 26 2 28
Blood donors’ serum 185 12 197
Total 224 25 249
Table 3 Comparison between rPGM-ELISA and IHA in
terms of sensitivity and specificity in diagnosis of ALA
using statistical analysis
Sensitivity IHA Total Fisher’s Exact Test
(p-value).00 1.00
rPGM-ELISA .00 0 5 5 0.620
1.00 2 17 19
Total 2 22 24
Specificity IHA Total Fisher’s Exact Test
(p-value).00 1.00
rPGM-ELISA .00 181 14 195 0.638
1.00 28 2 30
Total 209 16 225
Note: (.00): Negative; (1.00): Positive.
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of rPGM-ELISA was almost comparable to previously
reported recombinant proteins such as SREHP, Gal/
GalNAc-specific lectin and 29 kDa cysteine-rich surface
protein, which showed both sensitivity and specificity
ranging from 80% to 100% [16,34,39].
Conclusion
In conclusion, the novel rPGM protein used in an indirect
ELISA format developed in this study could be useful for
in-house routine diagnosis of ALA. Future studies will de-
termine whether rPGM-ELISA also detects antibodies
produced in amoebic dysentery and asymptomatic cases.
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